This trial is active, not recruiting.

Condition unspecified adult solid tumor, protocol specific
Treatments therapeutic nutritional supplementation, white wine, questionnaire administration
Sponsor Mayo Clinic
Collaborator National Cancer Institute (NCI)
Start date July 2009
End date September 2017
Trial size 140 participants
Trial identifier NCT00936728, 09-000862, NCI-2009-01130, R01CA124614, RC08C6


RATIONALE: It is not yet know whether white wine is more effective than a nutritional supplement in improving appetite.

PURPOSE: This randomized clinical trial is studying white wine to see how well it works compared with a nutritional supplement in improving appetite in patients with cancer

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose supportive care
Patients consume white wine twice daily for 3-4 weeks.
white wine
Given orally
questionnaire administration
Ancillary studies
(Active Comparator)
Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.
therapeutic nutritional supplementation
Given orally
questionnaire administration
Ancillary studies

Primary Outcomes

Difference in the percentage of patients who report an improvement in their appetite over the intervention period
time frame: First 3 weeks

Secondary Outcomes

Differences in the percentage of patients who manifest weight stability, defined as weight gain of at least 5% of baseline
time frame: At one month
Overall survival
time frame: Every 6 months for 2 years
Incidence of study intervention-related toxicity
time frame: Prior to registration and at week 3-4
Patient-reported quality of life (QOL) as measured by the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) appetite scale
time frame: Prior to study intervention and then weekly

Eligibility Criteria

Male or female participants at least 21 years old.

Inclusion Criteria: - Incurable, invasive malignancy - Able to reliably take the study intervention as prescribed in this protocol - No prior or current history of alcoholism - Alert and mentally competent - Physician estimates that patient has lost >= 5 pounds (2.3 kg) in weight =< 2 months (excluding peri-operative weight loss; documented weight loss not required) and/or have estimated caloric intake of < 20 cal/kg daily (no further documentation necessary other than an affirmative answer to this statement) - Patient perceives loss of appetite and/or weight as a problem; NOTE: Documentation not necessary - Concurrent chemotherapy and/or radiotherapy are permitted - Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only - Willingness to abstain completely from alcohol for 4 weeks, except as prescribed in this trial; NOTE: Patients assigned to the non-wine nutritional supplement (Arm B) must be willing to abstain from wine and other alcoholic beverages for 3-4 weeks; Patients assigned to the white wine (Arm A) are allowed to take a nutritional supplement, such as Ensure or Boost if they choose to - Ability to complete questionnaire(s) by themselves or with assistance - Willingness to return to MCCRC enrolling institution for follow-up - Patients in whom the use of progestational agents is anticipated are not permitted to be on this study - Short-term use of dexamethasone around days of intravenous chemotherapy is allowed for protection against emesis, but dexamethasone for appetite stimulation is not permitted Exclusion Criteria: - Receiving tube feedings or parenteral nutrition - Current (=< 1 month) or planned treatment with adrenal corticosteroids (short-term use of dexamethasone around days of chemotherapy is allowed for protection against emesis), androgens, or progestational agents; EXCEPTION: Inhalant, topical, or optical steroid use is permissible - Progestational agent (such as megestrol acetate) planned to be initiated over the next 30 days; NOTE: Patients who have been on megestrol acetate for > 1 month and are still on it and otherwise meet the eligibility criteria are permitted to enroll on this protocol and remain on megestrol acetate - Known mechanical obstruction of the alimentary tract, malabsorption, or intractable vomiting (> 5 episodes/week) - Symptomatic or untreated brain metastases - Any of the following as this regimen may be harmful to a developing fetus or nursing child: pregnant women, nursing women, and men or women of childbearing potential who are unwilling to employ adequate contraception

Additional Information

Official title White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Principal investigator Tom R. Fitch, M.D.
Description OBJECTIVES: I. To compare white wine (Arm A) to non-wine nutritional supplement (Arm B) for the treatment of cancer-associated anorexia. II. To evaluate the side effect profile of white wine (Arm A). OUTLINE: Patients are stratified according to primary malignant disease (lung vs gastrointestinal vs other [specify]), severity of weight loss (excluding peri-operative weight loss) within the past 2 months (< 4.6 kg [< 10 lbs] vs >= 4.6 kg [>= 10 lbs]), age (< 50 years vs >= 50 years), and planned concurrent chemotherapy or radiation (yes vs no). Patients are randomized to 1 of 2 arms. ARM A: Patients consume white wine with =< 15% alcohol content twice daily for 3-4 weeks. ARM B: Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks. After completion of study treatment, patients are followed up every 6 months for 2 years.
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by Mayo Clinic.